Magid A Fahim1, Andrew Hayen2, Andrea R Horvath3, Goce Dimeski4, Amanda Coburn5, David W Johnson6, Carmel M Hawley6, Scott B Campbell7, Jonathan C Craig8. 1. Departments of Nephrology and School of Medicine and Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia; magid.fahim@health.qld.gov.au. 2. School of Medical Sciences, University of New South Wales, Sydney, Australia; 3. School of Public Health, University of Sydney, Sydney, Australia; Department of Clinical Chemistry, Prince of Wales Hospital, South Eastern Area Laboratory Services, Sydney, Australia; and School of Medical Sciences, University of New South Wales, Sydney, Australia; 4. School of Medicine and Chemical Pathology, Pathology Queensland, Princess Alexandra Hospital, Brisbane, Queensland, Australia; 5. Departments of Nephrology and. 6. Departments of Nephrology and School of Medicine and Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia; 7. Departments of Nephrology and School of Medicine and. 8. School of Public Health, University of Sydney, Sydney, Australia; Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, Australia.
Abstract
BACKGROUND AND OBJECTIVES: Monitoring N-terminal pro-B-type natriuretic peptide (NT-proBNP) may be useful for assessing cardiovascular risk in dialysis patients. However, its biologic variation is unknown, hindering the accurate interpretation of serial concentrations. The aims of this prospective cohort study were to estimate the within- and between-person coefficients of variation of NT-proBNP in stable dialysis patients, and derive the critical difference between measurements needed to exclude biologic and analytic variation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Fifty-five prevalent hemodialysis and peritoneal dialysis patients attending two hospitals were assessed weekly for 5 weeks and then monthly for 4 months between October 2010 and April 2012. Assessments were conducted at the same time in the dialysis cycle and entailed NT-proBNP testing, clinical review, electrocardiography, and bioimpedance spectroscopy. Patients were excluded if they became unstable. RESULTS: This study analyzed 136 weekly and 113 monthly NT-proBNP measurements from 40 and 41 stable patients, respectively. Results showed that 22% had ischemic heart disease; 9% and 87% had left ventricular systolic and diastolic dysfunction, respectively. Respective between- and within-person coefficients of variation were 153% and 27% for weekly measurements, and 148% and 35% for monthly measurements. Within-person variation was unaffected by dialysis modality, hydration status, inflammation, or cardiac comorbidity. NT-proBNP concentrations measured at weekly intervals needed to increase by at least 46% or decrease by 84% to exclude change due to biologic and analytic variation alone with 90% certainty, whereas monthly measurements needed to increase by at least 119% or decrease by 54%. CONCLUSIONS: The between-person variation of NT-proBNP was large and markedly greater than within-person variation, indicating that NT-proBNP testing might better be applied in the dialysis population using a relative-change strategy. Serial NT-proBNP concentrations need to double or halve to confidently exclude change due to analytic and biologic variation alone.
BACKGROUND AND OBJECTIVES: Monitoring N-terminal pro-B-type natriuretic peptide (NT-proBNP) may be useful for assessing cardiovascular risk in dialysis patients. However, its biologic variation is unknown, hindering the accurate interpretation of serial concentrations. The aims of this prospective cohort study were to estimate the within- and between-person coefficients of variation of NT-proBNP in stable dialysis patients, and derive the critical difference between measurements needed to exclude biologic and analytic variation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Fifty-five prevalent hemodialysis and peritoneal dialysis patients attending two hospitals were assessed weekly for 5 weeks and then monthly for 4 months between October 2010 and April 2012. Assessments were conducted at the same time in the dialysis cycle and entailed NT-proBNP testing, clinical review, electrocardiography, and bioimpedance spectroscopy. Patients were excluded if they became unstable. RESULTS: This study analyzed 136 weekly and 113 monthly NT-proBNP measurements from 40 and 41 stable patients, respectively. Results showed that 22% had ischemic heart disease; 9% and 87% had left ventricular systolic and diastolic dysfunction, respectively. Respective between- and within-person coefficients of variation were 153% and 27% for weekly measurements, and 148% and 35% for monthly measurements. Within-person variation was unaffected by dialysis modality, hydration status, inflammation, or cardiac comorbidity. NT-proBNP concentrations measured at weekly intervals needed to increase by at least 46% or decrease by 84% to exclude change due to biologic and analytic variation alone with 90% certainty, whereas monthly measurements needed to increase by at least 119% or decrease by 54%. CONCLUSIONS: The between-person variation of NT-proBNP was large and markedly greater than within-person variation, indicating that NT-proBNP testing might better be applied in the dialysis population using a relative-change strategy. Serial NT-proBNP concentrations need to double or halve to confidently exclude change due to analytic and biologic variation alone.
Authors: Kirsten Bibbins-Domingo; Reena Gupta; Beeya Na; Alan H B Wu; Nelson B Schiller; Mary A Whooley Journal: JAMA Date: 2007-01-10 Impact factor: 56.272
Authors: F Mallamaci; C Zoccali; G Tripepi; F A Benedetto; S Parlongo; A Cataliotti; S Cutrupi; G Giacone; I Bellanuova; B Stancanelli; L S Malatino Journal: Kidney Int Date: 2001-04 Impact factor: 10.612
Authors: B Stanek; B Frey; M Hülsmann; R Berger; B Sturm; J Strametz-Juranek; J Bergler-Klein; P Moser; A Bojic; E Hartter; R Pacher Journal: J Am Coll Cardiol Date: 2001-08 Impact factor: 24.094
Authors: Alan H B Wu; Andrew Smith; Stacey Wieczorek; Jeffrey F Mather; Bret Duncan; C Michael White; Carol McGill; Deb Katten; Gary Heller Journal: Am J Cardiol Date: 2003-09-01 Impact factor: 2.778
Authors: Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer Journal: JAMA Date: 2003-01-08 Impact factor: 56.272
Authors: Riccardo Maria Fagugli; Barbara Palumbo; Daniela Ricciardi; Paolo Pasini; Paola Santirosi; Luigi Vecchi; Franca Pasticci; Renato Palumbo Journal: Nephron Clin Pract Date: 2003
Authors: Crina Claudia Rusu; Simona Racasan; Diana Moldovan; Alina Potra; Dacian Tirinescu; Cristian Budurea; Remus Orasan; Ioan Mihai Patiu; Cosmina Bondor; Dan Vladutiu; Dan Delean; Alexandra Danu; Ina Maria Kacso Journal: Int Urol Nephrol Date: 2018-07-13 Impact factor: 2.370
Authors: Franz Maximilian Rasche; Stephan Stoebe; Thomas Ebert; Silvana Feige; Andreas Hagendorff; Wilma Gertrud Rasche; Filip Barinka; Volker Busch; Ulrich Sack; Jochen G Schneider; Stephan Schiekofer Journal: BMC Nephrol Date: 2017-05-30 Impact factor: 2.388
Authors: Leonie Grossekettler; Bastian Schmack; Katrin Meyer; Carsten Brockmann; Reinhard Wanninger; Michael M Kreusser; Lutz Frankenstein; Lars P Kihm; Martin Zeier; Hugo A Katus; Andrew Remppis; Vedat Schwenger Journal: ESC Heart Fail Date: 2019-02-27
Authors: Leonie Grossekettler; Bastian Schmack; Carsten Brockmann; Reinhard Wanninger; Michael M Kreusser; Lutz Frankenstein; Lars P Kihm; Martin Zeier; Hugo A Katus; Vedat Schwenger; Andrew Remppis Journal: BMC Nephrol Date: 2020-05-14 Impact factor: 2.388